BlackRock Advisors’s HTG Molecular Diagnostics, Inc. Common Stock HTGM Stock Holding History

BlackRock Advisors’s Portfolio HTGM Stock Details HTGM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-1,511	Closed	-$617K	–	3750
2016 Q3	$617K	Sell	1,511 -127	-8%	-$56.8K	﹤0.01%	2069
2016 Q2	$802K	Sell	1,638 -611	-27%	-$310K	﹤0.01%	1865
2016 Q1	$1.16M	Sell	2,249 -324	-13%	-$181K	﹤0.01%	1666
2015 Q4	$2.02M	Hold	2,573	–	–	﹤0.01%	1405
2015 Q3	$3.53M	Hold	2,573	–	–	﹤0.01%	1201
2015 Q2	$5.17M	Buy	+2,573	New	+$6.57M	0.01%	987

Other funds holding HTGM

NHAS

Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

SIM

Sonora Investment Management Tucson, Arizona $798M AUM 17.61% 1-Year Est. Return

Ironwood Financial Tucson, Arizona $639M AUM 19.03% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

BlackRock Advisors's HTGM Position: Q4 2016 in Review

BlackRock Advisors sold out of HTG Molecular Diagnostics, Inc. Common Stock (HTGM) in Q4 2016, closing a stake of 1,511 shares — an estimated $617K sold.

BlackRock Advisors first reported a position in HTGM in Q2 2015 and held it in 6 quarters. The position peaked at $5.17M in Q2 2015. 13 funds tracked by Wall St. Rank hold HTGM as of Q4 2016.

BlackRock Advisors reported no remaining HTG Molecular Diagnostics, Inc. Common Stock position as of Q4 2016 after selling out during the quarter.
BlackRock Advisors sold 1,511 HTG Molecular Diagnostics, Inc. Common Stock shares in Q4 2016, an estimated $617K.
BlackRock Advisors first reported a position in HTG Molecular Diagnostics, Inc. Common Stock in Q2 2015 and held it in 6 quarters.
BlackRock Advisors's HTG Molecular Diagnostics, Inc. Common Stock position peaked at $5.17M in Q2 2015.
13 funds tracked by Wall St. Rank held HTG Molecular Diagnostics, Inc. Common Stock as of Q4 2016.

Based on BlackRock Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.